A Randomized Clinical Study on Combination of Concurrent Chemo-Radiotherapy and Thalidomide for Middle-Late Esophageal Cancer

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Fig. 1.
Comparison of survival curves between the experiment and control groups.

Table 1.

Comparison of the clinical data from the cases in the 2 groups.

Characteristics	TG (n = 33)	CG (n = 32)	χ²	P
Sex			0.1232	0.7256
Male	23	21
Female	10	11
Age, years			0.4713	0.4924
< 60	20	22
≥ 60	13	10
Diseased region			0.6574	0.8832
Cervical segment	5	3
Superior thoracic segment	11	10
Middle thoracic segment	15	17
Inferior thoracic segment	2	2
Size of foci (cm)			0.4184	0.5177
≤ 5	7	9
> 5	26	23

Table 4.

Comparison of side effects in the 2 groups (case).

Side effects	TG (n = 33)			CG (n = 32)			χ²	P
Side effects	I-II	III-IV	Incidence (%)	I-II	III-IV	Incidence (%)	χ²	P
Radioactive esophagitis	9	2	33.3	8	3	34.4	0.0079	0.9293
Nausea, vomiting	10	2	36.4	12	8	62.5	4.4402	0.0351
Leukopenia	11	3	42.4	10	2	37.5	0.1641	0.6854
HB	9	1	30.3	13	2	46.9	1.8851	0.1698
PLT	8	0	24.2	7	1	25.0	0.0050	0.9435
Radioactive skin destruction	9	8	51.5	11	6	53.1	0.0169	0.8966
Constipation	19	7	78.8	12	3	46.9	7.1042	0.0077
Rash or pruritus	6	1	21.2	0	0	0	7.6071	0.0058
Dizziness or lethargy	17	6	69.7	5	1	18.8	17.0653	0.0000
Liver function	4	0	12.1	2	0	6.3	0.6684	0.4136
Renal function	2	0	6.1	3	0	9.4	0.2513	0.6161